Vitamin D Status in Israeli Subjects before the Initiation and after the Cessation of Vitamin D Supplements

被引:0
作者
Walid Saliba
Ofra Barnett
Hedy S. Rennert
Idit Lavi
Gad Rennert
机构
[1] Technion–Israel Institute of Technology,Department of Community Medicine and Epidemiology, Carmel Medical Center, Clalit Health Services, and Bruce Rappaport Faculty of Medicine
[2] Office of the Chief Physician,Department of Epidemiology and Disease Prevention
[3] Clalit Health Services Headquarters,undefined
来源
Calcified Tissue International | 2011年 / 89卷
关键词
Cholecalciferol; Vitamin D; 25OHD; Treatment cessation;
D O I
暂无
中图分类号
学科分类号
摘要
Vitamin D supplements are often recommended to restore sufficiency, although the adherence to treatment is low. This study assessed vitamin D status at different time intervals following the cessation of treatment. The database of Clalit-Health-Services (CHS), a not-for-profit HMO covering more than half of the Israeli population, was retrospectively searched for all members with available serum 25OHD test results in 2009 (245,493). We then identified those who filled any cholecalciferol prescription in 2008–2009 (121,817). Subjects were included in the final analysis only if they started treatment in 2009, had serum 25OHD < 50 nmol/l before the first prescription in 2009, and had at least one additional test result after the last dated prescription in 2009 (5,461). Serum 25OHD increased from 32 ± 11 nmol/l at baseline to 58.6 ± 22.3 nmol/l after treatment (P < 0.001). The proportion of subjects with sufficient vitamin D after treatment increased with increasing cholecalciferol daily dose and treatment duration (P < 0.001) and decreased with increasing time from cessation of treatment (P < 0.001). The effect of time from treatment cessation persisted after controlling for baseline serum 25OHD, daily cholecalciferol dose, treatment duration, seasonality, gender, age, ethnicity, and BMI; the ORs for sufficient vitamin D were 2.02 (95% CI 1.66–2.45), 1.67 (1.39–2.01), and 1.23 (1.04–1.47) for >30–60, 61–99, and 100–155 days compared to >155 days, respectively. Long-term vitamin D treatment is needed to maintain sufficient levels in those with baseline serum 25OHD below 50 nmol/l.
引用
收藏
页码:419 / 425
页数:6
相关论文
共 125 条
[1]  
Spina CS(2006)Vitamin D and cancer Anticancer Res 26 2515-2524
[2]  
Tangpricha V(2010)Low serum 25-hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general population: The Tromsø study Eur J Endocrinol 162 935-942
[3]  
Uskokovic M(2006)High prevalence of vitamin D inadequacy and implications for health Mayo Clin Proc 81 353-373
[4]  
Adorinic L(2011)The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know J Clin Endocrinol Metab 96 53-58
[5]  
Maehr H(2007)Vitamin D deficiency N Engl J Med 357 266-281
[6]  
Holick MF(2009)IOF Committee of Scientific Advisors (CSA) Nutrition Working Group (2009) Global vitamin D status and determinants of hypovitaminosis D Osteoporos Int 20 1807-1820
[7]  
Hutchinson MS(1998)Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men Osteoporos Int 8 222-230
[8]  
Grimnes G(2008)Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration Am J Clin Nutr 87 1952-1958
[9]  
Joakimsen RM(2007)Dose response to vitamin D supplementation among postmenopausal African American women Am J Clin Nutr 86 1657-1662
[10]  
Figenschau Y(1999)Vitamin D supplementation in postmenopausal black women J Clin Endocrinol Metab 84 3988-3990